Reckitt Benckiser Group

INSURERS' CONUNDRUM

12/02/20 -"In these daily short papers, we have repeatedly marvelled at the outperformance of insurers in a negative rate context. What is good news to magnify re-insurers’ top-notch investment portfolios ..."

PDF page sample
Pages
51
Language
English
Published on
12/02/20
Download
You may also be interested by these reports :
10/11/25
The Q3 2025 results came largely as expected, with Adhesive Technologies performing in line, driven by its futuristic solutions. Consumer Brands ...
03/11/25
Puig delivered an impressive Q3 25, beating expectations with extraordinary momentum in makeup and solid progress in Asia. The group raised its FY25 ...
30/10/25
Haleon’s Q3 sales aligned with expectations, driven by growth in Oral Health, VMS, Pain Relief, and Digestive Health. This was partially offset by ...
30/10/25
Essity delivered a profit beat for Q3 2025, with an Adj. EBITA of SEK 5,056m and an impressive 14.6% margin, exceeding consensus despite in-line net ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO